Evidence Base Online reports The Institute for Clinical and Economic Review (ICER; MA, USA) has announced it is to update its 2018 value assessment concerning three treatments indicated for long-term prophylaxis against hereditary angioedema attacks. ICER is to incorporate observational real-world evidence, analyzed using the Aetion Evidence Platform®, in the new pilot to help further clarify the value of the therapies.
Read More
Read More